|
The Need
The limited volume of blood collected from the Umbilical Cord substantially limits the ability to fully exploit its potential.
Currently, the average volume of blood collected restricts the therapeutic use of Cord Blood Stem Cells (CBSCs) to patients weighing an average of only about 27kg (57 lbs), which eliminates the majority of adult patients.
There is a need for a simple, reproducible, low-cost – fully sterile – not contaminated method to increase the quality and quantity of Cord Blood collected and the number of Stem Cells extracted.
The SituGen Solution
- SituGen has developed the SituGen novel device for effective, reproducible and cost-effective – fully sterile – method to increase the quality of Cord Blood collected and the number of Stem Cells extracted.
- SituGen’s solution is a disposable comprehensive, all-inclusive kit for CBSC collection, designed to solve the problem of blood quantity and maximize the volume of UCB and the number and quality of Stem Cells extracted.
- The Situgen novel device is needle-free, relieving the “bottleneck” affect created due to a needle.
- The SituGen device is fully disinfected and sterilized according to the requirements for all blood collection devices.
Advantages/Features
- First and only device capable of extracting sufficient quantities of Stem Cells for transplantation in most adult patients
- Completely Closed & Sterile environment collection
- Definite increase in Stem Cell quantity & quality
- Less dependant on collector expertise
- Needle Free
- Disposable
- Cost effective, High ROI
Traditional method SituGen
|
“Open” collection in a complete, fully sterile, hermetically Closed environment, needle-free! |
Traditional, Passive Method 16G 1/2) mm diameter) needle inserted into a 4mm vein causes a bottle-neck |
|
Average of 102 mL 13.1 x 10^8 TNC 73%) of the after birth residual blood in the Placenta) |
Average of 60 mL - 4.7 x 10^8 TNC in Private Banks, 89 mL 10.4 x 10^8 TNC in Public Banks (less than half the blood in the Placenta) |
|
Maternal Cells presence in 0% of the samples |
Maternal Cells presence in up to 15% of the samples |
|
Serves patients weighing 59 Kg (106 lbs) in average |
Serves only patients weighing up
to 35 kg (77 lbs) in Average |
|
Children & adults |
Mainly children |
|
The SituGen is a comprehensive, all-inclusive Collection Kit(*) |
The Blood Donor Bag is one component in the Collection Kit |
(*) A sterile blister including peripheral assisting items for successful collection.
Development Status
- Clinical trials have been conducted at one of Israel's major Medical Centers and the device was launched in Israel in 2009.
- Patent applications were filed covering the apparatus and method for collecting human cord blood from the placenta and the umbilical cord. The regulatory process (FDA and CE) has been initiated and is expected to be completed soon.
- The SituGen device is expected to be available for international marketing during 2018.
- SituGen has already initiated an advanced R&D program - the Cord Blood coagulation aspects in the Placenta - Umbilical Cord System.
SituGen's brochure Click here.
SituGen's marketing presentation Click here.
SituGen's Presentation Click here.
מיקי שחם |
